|
Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer Clinical research trials and Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer. Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer  Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer
Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer
For Condition: adenocarcinoma of the rectum,recurrent rectal cancer,adenocarcinoma of the colon,Stage 4 rectal cancer,stage 4 colon cancer,stage 3 rectal cancer,childhood gastrointestinal cancer,stage 3 colon cancer,Quality of Life,recurrent colon cancer
Status: No longer recruiting
Sponsor(s): Medical Research Council ,
Synopsis: RATIONALE: Palliative chemotherapy may help patients with advanced colorectal cancer live longer and more comfortably. PURPOSE: Randomized phase III trial to compare the effectiveness of and quality of life following three different palliative chemotherapy regimens in treating patients with advanced metastatic or recurrent colorectal cancer.
Details: OBJECTIVES: I. Compare the survival and quality of life of patients with metastatic or recurrent colorectal cancer receiving palliative therapy with leucovorin/fluorouracil vs. continuous-infusion fluorouracil vs. ICI D1694. II. Compare the survival and quality of life of patients with stable or responding disease after 12 weeks of initial treatment randomized to receive 12 additional weeks of chemotherapy vs. no further treatment. PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by participating institution. Patients are randomized to one of three treatment regimens. The first group receives leucovorin followed by fluorouracil every 14 days for a total of 6 courses. The second group receives continuous-infusion fluorouracil for 12 weeks. The third group receive ICI D1694 every 21 days for a total of 4 courses. Patients without progressive disease or excessive toxicity after 12 weeks of treatment are then randomized to receive continuing chemotherapy in 12 weekly cycles of their assigned chemotherapy or to proceed to observation with no further therapy, until evidence of disease progression. Patients are followed every 6 weeks. PROJECTED ACCRUAL: A total of 900 patients will be entered.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed adenocarcinoma of the colon or rectum in one of the following categories: Locally advanced, metastatic, or recurrent disease suitable only for palliative chemotherapy - Evaluable disease outside prior radiotherapy field - Patients with disease confined to the liver are referred to protocol MRC-CR05 --Prior/Concurrent Therapy-- - No prior systemic chemotherapy except fluorouracil-based adjuvant regimen (e.g., QUASAR); At least 6 months since chemotherapy --Patient Characteristics-- - Age: Not specified - Performance status: WHO 0-2 - Life expectancy: Greater than 3 months - Hematopoietic: WBC at least 4,000 ANC at least 2,000; Platelets at least 100,000 - Hepatic: Not specified - Renal: Creatinine no greater than 1.25 times normal OR Creatinine clearance greater than 65 mL/min - Cardiovascular: No uncontrolled heart failure; No uncontrolled angina - Other: No uncontrolled medical illness (including infection); Able and willing to complete quality-of-life questionnaires; No prior or concurrent malignancy likely to interfere with protocol treatment or evaluation
Total Enrollment:
Location and Contact Information:
Overall Study Official:
TimothyMaughan, Study Chair, Medical Research Council
Velindre Hospital
Cardiff, Wales, CF4 7XL
United Kingdom
Additional Information:
Study ID Numbers: CDR0000065216; MRC-CR06,EU-96049
Study Start Date: June 1995
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002893
Other Adenocarcinoma Of The Rectum Studies:
1. Tocladesine in Treating Patients With Recurrent or Progressive Metastatic Colorectal Cancer
2. Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer
3. Cetuximab and Best Supportive Care Compared With Best Supportive Care Alone in Treating Patients With Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer
4. Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer
5. Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
Related Studies:
Other adenocarcinoma of the rectum Clinical Trials
Other Wales Clinical Trials
Other Cardiff Clinical Trials
Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer
|
|
|
|
|
|
|
|
